Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Obrixtamig · 1 trial · 4 indications
Progression-free survival (PFS) is defined as the time from first investigational medicinal product (IMP) administration until the earliest date of disease progression according to Response Evaluation Criteria In Solid Tumours (RECIST 1.1) based on investigator assessments or death from any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Part 1: obrixtamig + ZL-1310 (dosing regimen 1) | EXPERIMENTAL | - |
| Part 1: obrixtamig + ZL-1310 (dosing regimen 2) | EXPERIMENTAL | - |
| Part 2: obrixtamig + ZL-1310 + atezolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Obrixtamig | DRUG | Obrixtamig |
| ZL-1310 | DRUG | ZL-1310 |
| Atezolizumab | DRUG | Atezolizumab |
Inclusion criteria: For Part 1 1. Diagnosed with locally advanced, metastatic or relapsed cancer of the following histologies: * Small cell lung carcinoma (SCLC) * Large cell neuroendocrine lung carcinoma (LCNEC-L) * Extrapulmonary neuroendocrine carcinoma (epNEC) of small or large cell ...
Top 20 of 84 competitors
Obrixtamig is an investigational small molecule being studied for the treatment of advanced Small Cell Lung Cancer and other neuroendocrine cancers. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in combination with another investigational agent, ZL-1310.
Obrixtamig is being developed by Zai Lab Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ZLAB. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and efficacy in patients with advanced Small Cell Lung Cancer and other neuroendocrine cancers.
Obrixtamig is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is designed to assess the drug in combination with ZL-1310 in patients with advanced Small Cell Lung Cancer or other neuroendocrine cancers.
Obrixtamig is being studied in a single Phase 1 clinical trial with the identifier NCT07707895, known as DAREON-36. This trial is evaluating Obrixtamig in combination with ZL-1310 in approximately 60 patients with advanced Small Cell Lung Cancer or other neuroendocrine cancers. The trial is not yet recruiting participants.
No, Obrixtamig and ZL-1310 are two different investigational drugs. The Phase 1 clinical trial NCT07707895 is testing Obrixtamig in combination with ZL-1310, meaning the two agents are being studied together. Obrixtamig is a small molecule developed by Zai Lab Limited, while ZL-1310 is a separate investigational compound.